What one share of aTYR PHARMA holds
We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans.
aTYR PHARMA’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.62 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.56 |
| Cash and investments | $0.16 |
| Book value | $0.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$397.39 | $11.82 | −$329.55 | — | −$1,213 |
| 2014 | — | −$415.63 | $4.18 | −$387.21 | — | −$1,400 |
| 2015 | — | −$42.42 | $0.59 | −$33.11 | — | $68.05 |
| 2016 | — | −$34.20 | $0.35 | −$31.61 | — | $37.03 |
| 2017 | — | −$26.13 | $0.71 | −$23.67 | — | $30.19 |
| 2018 | — | −$16.11 | $0.28 | −$14.78 | — | $15.39 |
| 2020 | $1.14 | −$1.77 | $0.02 | −$1.69 | — | $2.87 |
| 2021 | — | −$1.77 | $0.01 | −$1.74 | — | $3.93 |
| 2022 | $0.37 | −$1.60 | $0.06 | −$1.53 | — | $2.42 |
| 2023 | $0.01 | −$0.94 | $0.08 | −$0.70 | — | $1.43 |
| 2024 | $0.00 | −$0.86 | $0.00 | −$0.93 | — | $0.83 |
| 2025 | $0.00 | −$0.80 | $0.00 | −$0.67 | — | $0.69 |
Common questions about aTYR PHARMA
How much does one share of aTYR PHARMA earn?
Over the last 12 months, aTYR PHARMA lost $0.62 for each share.
Does aTYR PHARMA pay a dividend?
aTYR PHARMA didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is aTYR PHARMA’s book value per share?
aTYR PHARMA’s book value is $0.50 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of aTYR PHARMA have?
Each share of aTYR PHARMA has $0.16 of cash and investments, as of June 30, 2026.
What is aTYR PHARMA’s free cash flow per share?
−$0.56 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has aTYR PHARMA bought back shares?
aTYR PHARMA’s share count rose about 170569% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.